Microbio profiled on Life Sciences Qld blog

Microbio is pleased to share the Case Study published by Life Sciences Queensland detailing the recent Federal Government Accelerating Commercialisation Grant and commercialisation progress of its pathogen detection products. Read more at: https://www.lsq.com.au/case-study/microbio-new-diagnostic-tests-to-improve-the-identification-of-pathogens/

Microbio obtains significant commercialisation grant

Microbio Pty Ltd, an Australian-owned biotech company has been awarded a Federal Government Accelerating Commercialisation Grant to commercialise Microbio’s InfectID-Blood Stream Infection (BSI) diagnostic assay. Read more in the full media release: 201123_Microbio_Release_CA_Grant_Success

Microbio announces development of replicating SARS-CoV-2 virus test

Microbio has developed a new type of COVID-19 test that has the potential to determine not only if someone has the virus but also if they are infectious. Microbio today announced its ground-breaking InfectID-COVID-19-R test which has been independently validated to identify the presence of replication-competent SARS-CoV-2 virus in samples in 45 minutes (post RNA extraction).  The full press kit and accompanying photographs can be… Continue reading Microbio announces development of replicating SARS-CoV-2 virus test

Dr Flavia Huygens receives DMTC Ltd 2020 Excellence Award

Dr Flavia Huygens has been honoured with one of DMTC’s 2020 Excellence Awards. Dr Huygens received the Project Leadership Award: “In recognition of exemplary professional conduct in support of DMTC’s objectives.” The awards evening was held during the DMTC Annual Conference, 11-12 March 2020 in Canberra. The conference highlights the projects building defence and national security… Continue reading Dr Flavia Huygens receives DMTC Ltd 2020 Excellence Award

Microbio SSBA Collaboration highlighted in 2019 DMTC Annual Report

The DMTC Medical Countermeasures Program has featured the collaboration with Microbio in the 2019 Annual Report. The collaboration aims to refine InfectID to diagnose seven security sensitive biological agents (SSBAs) without culture, so the technology can be used in field deployable clinical settings. https://issuu.com/dmtc-ltd/docs/dmtc_annual_report_2019 (see page 39)